The market opportunity for cancer drugs is vast. SciTech’s initial target markets are T-cell lymphoma ($250M) and Small Cell Lung Cancer (>$700M) for a total addressable market of $950M+. Potential efficacy is anticipated in other cancers.
SciTech’s initial target markets are T-cell lymphoma ($250M) and small cell lung cancer (>$700M) for a total initial addressable market of $950M+. The initial T-cell lymphoma addressable market reflect targeted subsets of the disease state; notably, PTCL+CTCL+AITL+Sezáry Syndrome (global prevalence of 7,400). While the small cell lung cancer addressable market reflects a global prevalence of 10,000.
Fenretinide is cytotoxic in various cancer cell lines, including neuroblastoma, leukemia, and lymphoma (Mohrbacher et al., 2007). Given below are cancer indications in which clinical or pre-clinical evidence supports the use of fenretinide as a therapeutic agent and represent SciTech’s future target markets (global values that could easily lead to a multi-billion-dollar addressable market).
SciTech’s focus is bringing to market a single-mode drug therapy; notably, ST-001 nanoFenretinide as a standalone drug treatment.
SciTech has entered into a collaborative agreement with Ferndale Laboratories Inc., which specializes in dermatological products, for a new topical drug application. SciTech and Ferndale are preparing IND filing of a topical formulation of ST-001 nanoFenretinide for skin cancer treatment, specifically: basal cell carcinoma, squamous cell carcinoma and actinic keratosis (AK, a precancerous condition) after having completed all preclinical studies.
Combination therapy opportunities may also avail themselves. These potential combination deals may be particularly attractive to SciTech as out-licensing or co-development opportunities for further revenue generation. Some possible combination deals include the following:
Fenretinide's unique modes of action makes ST-001 nanoFenretinide particularly well-suited for combination therapy. Specifically, ST-001 nanoFenretinide is ideally suited for combination therapies with existing oncology drugs as well as with the immuno-oncology drugs that have recently entered the market. In fact, ST-001 nanoFenretinide may provide synergy in combinations with the checkpoint inhibitors class of immunotherapy and related cancer drugs.
Stand-alone drug and drug combination strategies represent several multibillion-dollar market opportunities for SciTech. Additionally, SciTech's nanoparticle liposomal drug delivery technology holds the promise of enhancing the therapeutic performance of other cancer and non-cancer drugs with similar solubility profiles.
Value Proposition - Fenretinide has been uniquely validated by Phase I clinical trial data in the past. By reconfirming this efficacy and establishing the safety of ST-001 nanoFenretinide in a Phase I T-cell lymphoma trial,
SciTech will be enabling this anticancer agent’s much